Andrew Gabrielson
Overview
Explore the profile of Andrew Gabrielson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Patel S, Wang S, Metcalf M, Gupta N, Gabrielson A, Lee E, et al.
Clin Genitourin Cancer
. 2021 Dec;
20(1):60-68.
PMID: 34896022
Purpose: Muscle invasive bladder cancer surgical management has been historically a radical cystoprostatectomy in males and an anterior exenteration in females. Uterine, ovarian, and vaginal preservation are utilized, but raise...
12.
Choi W, Lombardo K, Patel S, Epstein G, Feng M, Gabrielson A, et al.
Eur Urol
. 2021 Nov;
81(2):138-142.
PMID: 34736796
The treatment landscape for advanced urothelial cancer has changed dramatically owing to the US Food and Drug Administration approval and introduction of antibody-drug conjugates (ADCs), including enfortumab vedotin and sacituzumab...
13.
Natale C, Gabrielson A, Nguyen H, Dick B, Hellstrom W
J Sex Med
. 2020 Oct;
17(11):2229-2235.
PMID: 33008782
Background: Postorgasmic illness syndrome (POIS) is a rare syndrome of unknown etiology where patients experience distressing physical and psychological after ejaculatory sequelae. Aim: To better characterize the epidemiology, symptomatology, disease...
14.
Pineault K, Ray S, Gabrielson A, Herati A
Transl Androl Urol
. 2020 May;
9(2):391-397.
PMID: 32420144
Background: Chronic prostatitis/chronic pelvic pain syndrome type III (CP/CPPS) is associated with pelvic pain, sexual dysfunction and irritative voiding. Sustained symptom relief has proven difficult with alpha blockers, antibiotics, and...
15.
Haney N, Gabrielson A, Kohn T, Hellstrom W
Sex Med Rev
. 2018 Jul;
7(2):313-320.
PMID: 29960873
Introduction: Stem cell therapy using stromal vascular fraction (SVF) is a promising treatment modality. SVF is comprised of a mixture of adipose-derived stem cells, endothelial precursor cells, and immune modulatory...
16.
Liu J, Wang M, Tulman D, Mandava S, Elfer K, Gabrielson A, et al.
Urology
. 2016 Sep;
98:195-199.
PMID: 27597632
Objective: To present a novel imaging technique used for rapid, nondestructive histological assessment of renal neoplasias using a dual-component fluorescence stain and structured illumination microscopy (SIM). Materials And Methods: After...
17.
Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, et al.
Cancer Immunol Res
. 2016 Mar;
4(5):419-30.
PMID: 26968206
Immune cells that infiltrate a tumor may be a prognostic factor for patients who have had surgically resected hepatocellular carcinoma (HCC). The density of intratumoral total (CD3(+)) and cytotoxic (CD8(+))...
18.
Gabrielson A, Miller A, Banovac F, Kim A, He A, Unger K
Front Oncol
. 2016 Jan;
5:292.
PMID: 26779437
Purpose: We sought to report outcomes and toxicity in patients with hepatocellular carcinoma (HCC) who received resin yttrium-90 selective internal radiation therapy ((90)Y-SIRT) and to identify factors associated with declining...
19.
Wu Z, Gabrielson A, Hwang J, Pishvaian M, Weiner L, Zhuang T, et al.
Cancer Chemother Pharmacol
. 2015 Oct;
76(6):1309-14.
PMID: 26507197
Purpose: Patients with metastatic, gemcitabine-refractory pancreatic cancer typically have poor survival. Erlotinib, a targeted therapy that inhibits epidermal growth factor receptor (EGFR) activity (overexpressed in 40-60 % of pancreatic cancers),...
20.
Gabrielson A, Tesfaye A, Marshall J, Pishvaian M, Smaglo B, Jha R, et al.
Cancer Chemother Pharmacol
. 2015 Oct;
76(5):1073-9.
PMID: 26449224
Purpose: To determine the antitumor efficacy and tolerability of combination temozolomide (TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular carcinoma (HCC). Methods: This single-arm phase II trial enrolled...